



## AN2 Therapeutics to Participate in Citizens JMP Life Sciences Conference

April 30, 2025

MENLO PARK, Calif.--(BUSINESS WIRE)--Apr. 30, 2025-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO will participate in a fireside chat at the 2025 Citizens JMP Life Sciences Conference being held from May 7-8, 2025 in New York.

Details of the event is as follows:

Citizens JMP Life Sciences Conference

- Eric Easom, Co-Founder, Chairman, President and CEO will participate in a fireside chat on Wednesday, May 7, 2025 at 9:00 am ET, and members of management will be available for 1X1 meetings.

A webcast can be accessed on the Investors section of the AN2 Therapeutics website at [www.an2therapeutics.com](http://www.an2therapeutics.com). An archived replay will be available for at least 30 days.

### About AN2 Therapeutics, Inc.

AN2 Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. AN2 has a pipeline of boron-based compounds in development for Chagas disease, NTM, and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. For more information, please visit our website at [www.an2therapeutics.com](http://www.an2therapeutics.com).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20250430523287/en/): <https://www.businesswire.com/news/home/20250430523287/en/>

### COMPANY CONTACT:

Lucy O. Day  
Chief Financial Officer  
[l.day@an2therapeutics.com](mailto:l.day@an2therapeutics.com)

### INVESTOR AND MEDIA CONTACT:

Anne Bowdidge  
[ir@an2therapeutics.com](mailto:ir@an2therapeutics.com)

Source: AN2 Therapeutics, Inc.